本刊稿约论文模板电子书
首页 > 过刊浏览>2025年第卷第3期 >404-417. DOI:10.7655/NYDXBNSN241237
PDF HTML阅读 XML下载 导出引用 引用提醒
帕金森病标志物α⁃突触核蛋白聚集抑制剂的研究进展
作者:
作者单位:

1.南京医科大学药学院，江苏 南京 211166 ;2.南京医科大学第一附属医院核医学科，江苏 南京 210029

基金项目:

国家自然科学基金（82373728，82473768）；江苏省自然科学基金（BK20231266）


Research progress on inhibitors of α ⁃ synuclein aggregation，a marker for Parkinson’s disease
Author:
Affiliation:

1.School of Pharmacy，Nanjing Medical University，Nanjing 211166 ;2.Department of Nuclear Medicine，the First Affiliated Hospital of Nanjing Medical University，Nanjing 210029 ，China

  • 摘要
    • | |
  • 访问统计
    • |
  • 参考文献 [75]
    • |
  • 相似文献 [20]
    • | | |
  • 文章评论
    摘要:

    帕金森病（Parkinson’s disease，PD）是第二大神经退行性疾病，α-突触核蛋白（α-synuclein，α-syn）的病理性聚集体是PD的生物标志物，与PD的发生发展密切相关。寻找一种在疾病早期就能够抑制病理性聚集体如α-syn寡聚体与α-syn原纤维形成的抑制剂，对治疗PD具有重要意义。近年来以α-syn为靶点的聚集抑制剂研究有了显著进展。文章综述了α-syn的结构、生理功能、病理机制和聚集抑制剂的研究进展，旨在为α-syn聚集抑制剂进一步研发提供参考。

    Abstract:

    Parkinson’s disease（PD）is the second most common neurodegenerative disease. The pathological aggregation of α- synuclein（α-syn）is a biomarker of PD，which is closely related to the occurrence and development of PD. Finding an inhibitor that can inhibit the formation of pathological aggregates such as α-syn oligomer and α-syn protofibrils at the early stage of the disease is of great significance for the treatment of PD. In recent years，significant progress has been made in the research of inhibitors targeting α-syn aggregation. This review summarizes the structure，physiological function，pathological mechanism and inhibitors of α-syn aggregation， aiming to provide a reference for the further research and development of α-syn aggregation inhibitors.

    参考文献
    [1] SINGH S K，DUTTA A，MODI G.α⁃ Synuclein aggregation modulation：an emerging approach for the treatment of Parkinson’s disease[J].Future Med Chem，2017，（9 10）：1039-1053
    [2] LUK K C，KEHM V，CARROLL J，et al.Pathological α⁃ synuclein transmission initiates Parkinson-like neurode-generation in nontransgenic mice[J].Science，2012，338（6109）：949-953
    [3] XU M M，RYAN P，RUDRAWAR S，et al.Advances in the development of imaging probes and aggregation inhibitors for alpha ⁃synuclein[J].Acta Pharmacol Sin，2020，41（4）：483-498
    [4] DEDMON M M，LINDORFF⁃LARSEN K，CHRISTODOU-LOU J，et al.Mapping long-range interactions in alpha-synuclein using spin⁃label NMR and ensemble molecular dynamics simulations[J].J Am Chem Soc，2005，127（2）：476-477
    [5] GROSSO JASUTKAR H，OH S E，MOURADIAN M M.Therapeutics in the pipeline targeting α ⁃ synuclein for Parkinson’s disease[J].Pharmacol Rev，2022，74（1）：207-237
    [6] BURRÉ J，SHARMA M，SÜDHOF T C.Cell biology and pathophysiology of α ⁃ synuclein[J].Cold Spring Harb Perspect Med，2018，8（3）：a024091
    [7] BERNAL⁃CONDE L D，RAMOS⁃ACEVEDO R，REYES-HERNÁNDEZ M A，et al.Alpha-synuclein physiology and pathology：a perspective on cellular structures and organelles[J].Front Neurosci，2019，13：1399
    [8] BARBUTI P A，OHNMACHT J，SANTOS B F R，et al.Gene-corrected p.A30P SNCA patient-derived isogenic neurons rescue neuronal branching and function[J].Sci Rep，2021，11（1）：21946
    [9] ZHAO K，LI Y W，LIU Z Y，et al.Parkinson’s disease associated mutation E46K of α⁃synuclein triggers the formation of a distinct fibril structure[J].Nat Commun，2020，11（1）：2643
    [10] SUN Y P，LONG H F，XIA W C，et al.The hereditary mutation G51D unlocks a distinct fibril strain transmissible to wild⁃type α⁃synuclein[J].Nat Commun，2021，12（1）：6252
    [11] TAMBASCO N，NIGRO P，ROMOLI M，et al.A53T in a parkinsonian family：a clinical update of the SNCA phenotypes[J].J Neural Transm，2016，123（11）：1301-1307
    [12] MOHITE G M，NAVALKAR A，KUMAR R，et al.The familial α⁃synuclein A53E mutation enhances cell death in response to environmental toxins due to a larger population of oligomers[J].Biochemistry，2018，57（33）：5014-5028
    [13] PORCARI R，PROUKAKIS C，WAUDBY C A，et al.The H50Q mutation induces a 10⁃fold decrease in the solubility of α⁃ synuclein[J].J Biol Chem，2015，290（4）：2395-2404
    [14] CABIN D E，SHIMAZU K，MURPHY D，et al.Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha⁃synuclein[J].J Neurosci，2002，22（20）：8797-8807
    [15] NEMANI V M，LU W，BERGE V，et al.Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis[J].Neuron，2010，65（1）：66-79
    [16] ZHAO X F，GUAN Y，LIU F W，et al.SNARE proteins mediate α ⁃ Synuclein secretion via multiple vesicular pathways[J].Mol Neurobiol，2022，59（1）：405-419
    [17] SCHASER A J，OSTERBERG V R，DENT S E，et al.Alpha-synuclein is a DNA binding protein that modulates DNA repair with implications for Lewy body disorders[J].Sci Rep，2019，9（1）：10919
    [18] KONTOPOULOS E，PARVIN J D，FEANY M B.Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity[J].Hum Mol Genet，2006，15（20）：3012-3023
    [19] DAGRA A，MILLER D R，LIN M，et al.α ⁃Synuclein-induced dysregulation of neuronal activity contributes to murine dopamine neuron vulnerability[J].NPJ Parkin-sons Dis，2021，7（1）：76
    [20] CHOI M L，CHAPPARD A，SINGH B P，et al.Pathological structural conversion of α⁃synuclein at the mitochondria induces neuronal toxicity[J].Nat Neurosci，2022，25（9）：1134-1148
    [21] MARTINEZ T N，GREENAMYRE J T.Toxin models of mitochondrial dysfunction in Parkinson’s disease[J].An-tioxid Redox Signal，2012，16（9）：920-934
    [22] NAKAMURA K，NEMANI V M，AZARBAL F，et al.Direct membrane association drives mitochondrial fission by the Parkinsons disease⁃associated protein alpha⁃synu-clein[J].J Biol Chem，2011，286（23）：20710-20726
    [23] CHEN L N，XIE Z G，TURKSON S，et al.A53T human α ⁃ synuclein overexpression in transgenic mice induces pervasive mitochondria macroautophagy defects preceding dopamine neuron degeneration[J].J Neurosci，2015，35（3）：890-905
    [24] DI MAIO R，BARRETT P J，HOFFMAN E K，et al.α⁃ Synuclein binds to TOM20 and inhibits mitochondrial protein import in Parkinson’s disease[J].Sci Transl Med，2016，8（342）：342ra78
    [25] SPRENKLE N T，SIMS S G，SÁNCHEZ C L，et al.Endoplasmic reticulum stress and inflammation in the central nervous system[J].Mol Neurodegener，2017，12（1）：42
    [26] COLLA E，JENSEN P H，PLETNIKOVA O，et al.Accumulation of toxic α⁃ synuclein oligomer within endoplasmic reticulum occurs in α⁃ synucleinopathy in vivo[J].J Neurosci，2012，32（10）：3301-3305
    [27] FUJITA Y，OHAMA E，TAKATAMA M，et al.Fragmentation of Golgi apparatus of nigral neurons with alpha⁃synu-clein ⁃ positive inclusions in patients with Parkinson’s disease[J].Acta Neuropathol，2006，112（3）：261-265
    [28] COOPER A A，GITLER A D，CASHIKAR A，et al.Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson’s models[J].Science，2006，313（5785）：324-328
    [29] XILOURI M，BREKK O R，STEFANIS L.α ⁃ Synuclein and protein degradation systems：a reciprocal relationship[J].Mol Neurobiol，2013，47（2）：537-551
    [30] WANG Q Q，LIU Y J，ZHOU J W.Neuroinflammation in Parkinson’s disease and its potential as therapeutic target[J].Transl Neurodegener，2015，4：19
    [31] LONG H F，ZHANG S N，ZENG S Y，et al.Interaction of RAGE with α ⁃ synuclein fibrils mediates inflammatory response of microglia[J].Cell Rep，2022，40（12）：111401
    [32] ANTONSCHMIDT L，MATTHES D，DERVIŞOĞLU R，et al.The clinical drug candidate anle138b binds in a cavity of lipidic α⁃synuclein fibrils[J].Nat Commun，2022，13（1）：5385
    [33] WAGNER J，RYAZANOV S，LEONOV A，et al.An-le138b：a novel oligomer modulator for disease⁃modifying therapy of neurodegenerative diseases such as prion and Parkinson’s disease[J].Acta Neuropathol，2013，125（6）：795-813
    [34] LEVIN J，SCHMIDT F，BOEHM C，et al.The oligomer modulator anle138b inhibits disease progression in a Parkinson mouse model even with treatment started after disease onset[J].Acta Neuropathol，2014，127（5）：779-780
    [35] HERAS⁃GARVIN A，WECKBECKER D，RYAZANOV S，et al.Anle138b modulates α ⁃ synuclein oligomerization and prevents motor decline and neurodegeneration in a mouse model of multiple system atrophy[J].Mov Disord，2019，34（2）：255-263
    [36] BRENDEL M，DEUSSING M，BLUME T，et al.Late⁃stage anle138b treatment ameliorates tau pathology and metabolic decline in a mouse model of human Alzheimer’s disease tau[J].Alzheimers Res Ther，2019，11（1）：67
    [37] ALECU J E，SIGUTOVA V，BRAZDIS R M，et al.NPT100⁃ 18A reduces mitochondrial oxidative stress and rescues neuronal cell death in a human iPSC⁃based model of Par-kinson’s disease[J].Research Square，2023，DOI：10.21203/RS.3.RS⁃3311240/V1
    [38] WRASIDLO W，TSIGELNY I F，PRICE D L，et al.A de novo compound targeting α⁃synuclein improves deficits in models of Parkinson’s disease[J].Brain，2016，139（Pt 12）：3217-3236
    [39] DAS D，BHARADWAZ P，MATTAPARTHI V S K.Computational investigation on the effect of the peptidomimetic inhibitors（NPT100⁃18A and NPT200⁃11）on the α⁃synu-clein and lipid membrane interactions[J].J Biomol Struct Dyn，2024，42（21）：11471-11482
    [40] PRICE D L，KOIKE M A，KHAN A，et al.The small molecule alpha-synuclein misfolding inhibitor，NPT200 ⁃ 11，produces multiple benefits in an animal model of Parkin-son’s disease[J].Sci Rep，2018，8（1）：16165
    [41] JING X N，SHI Q Y，BI W，et al.Rifampicin protects PC12 cells from rotenone ⁃induced cytotoxicity by activating GRP78 via PERK-eIF2α ⁃ ATF4 pathway[J].PLoS One，2014，9（3）：e92110
    [42] LIANG Y R，ZHENG D Z，PENG S D，et al.Rifampicin attenuates rotenone-treated microglia inflammation via improving lysosomal function[J].Toxicol In Vitro，2020，63：104690
    [43] WU X，LIANG Y R，JING X N，et al.Rifampicin prevents SH-SY5Y cells from rotenone ⁃induced apoptosis via the PI3K/Akt/GSK ⁃ 3β/CREB signaling pathway[J].Neuro-chem Res，2018，43（4）：886-893
    [44] STOILOVA T，COLOMBO L，FORLONI G，et al.A new face for old antibiotics：tetracyclines in treatment of amyloidoses[J].J Med Chem，2013，56（15）：5987-6006
    [45] MERLINI G，ASCARI E，AMBOLDI N，et al.Interaction of the anthracycline 4’⁃ iodo ⁃ 4’⁃ deoxydoxorubicin with amyloid fibrils：inhibition of amyloidogenesis[J].Proc Natl Acad Sci U S A，1995，92（7）：2959-2963
    [46] LI H T，LIN D H，LUO X Y，et al.Inhibition of alpha-synuclein fibrillization by dopamine analogs via reaction with the amino groups of alpha⁃synuclein.Implication for dopaminergic neurodegeneration[J].FEBS J，2005，272（14）：3661-3672
    [47] LATAWIEC D，HERRERA F，BEK A，et al.Modulation of alpha-synuclein aggregation by dopamine analogs[J].PLoS One，2010，5（2）：e9234
    [48] XU B K，CHEN J，LIU Y H.Curcumin interacts with α⁃ synuclein condensates to inhibit amyloid aggregation under phase separation[J].ACS Omega，2022，7（34）：30281-30290
    [49] AHMAD B，LAPIDUS L J.Curcumin prevents aggregation in α⁃synuclein by increasing reconfiguration rate[J].J Biol Chem，2012，287（12）：9193-9199
    [50] AHSAN N，MISHRA S，JAIN M K，et al.Curcumin pyrazole and its derivative n ⁃（3 ⁃ nitrophenylpyrazole）curcumin inhibit aggregation，disrupt fibrils and modulate toxicity of wild type and mutant α⁃synuclein[J].Sci Rep，2015，5：9862
    [51] GRELLE G，OTTO A，LORENZ M，et al.Black tea theafla-vins inhibit formation of toxic amyloid⁃β and α⁃synuclein fibrils[J].Biochemistry，2011，50（49）：10624-10636
    [52] ZHANG X，DU L D，ZHANG W，et al.Therapeutic effects of baicalein on rotenone-induced Parkinson’s disease through protecting mitochondrial function and biogenesis[J].Sci Rep，2017，7（1）：9968
    [53] XU Y，ZHANG Y Y，QUAN Z Z，et al.Epigallocatechin gallate（EGCG）inhibits alpha-synuclein aggregation：a potential agent for Parkinson’s disease[J].Neurochem Res，2016，41（10）：2788-2796
    [54] INDEN M，TAKAGI A，KITAI H，et al.Kaempferol has potent protective and antifibrillogenic effects for α⁃synu-clein neurotoxicity in vitro[J].Int J Mol Sci，2021，22（21）：11484
    [55] SUN C P，ZHOU J J，YU Z L，et al.Kurarinone alleviated Parkinson’s disease via stabilization of epoxyeicosatrienoic acids in animal model[J].Proc Natl Acad Sci USA，2022，119（9）：e2118818119
    [56] DEUS C M，PEREIRA S P，CUNHA⁃OLIVEIRA T，et al.A mitochondria-targeted caffeic acid derivative reverts cellular and mitochondrial defects in human skin fibroblasts from male sporadic Parkinson’s disease patients[J].Redox Biol，2021，45：102037
    [57] SINGH L.Daidzein’s potential in halting neurodegenera-tion：unveiling mechanistic insights[J/OL].Naunyn Schmie-debergs Arch Pharmacol，2024，DOI：10.1007/s00210 ⁃ 024⁃03356⁃5
    [58] SHAY J，ELBAZ H A，LEE I，et al.Molecular mechanisms and therapeutic effects of（⁃）⁃epicatechin and other polyphenols in cancer，inflammation，diabetes，and neuro-degeneration[J].Oxid Med Cell Longev，2015，2015：181260
    [59] ZHAI Y M，WANG T Y，FU Y M，et al.Ferulic acid：a review of pharmacology，toxicology，and therapeutic effects on pulmonary diseases[J].Int J Mol Sci，2023，24（9）：8011
    [60] GÜZELAD Ö，ÖZKAN A，PARLAK H，et al.Protective mechanism of syringic acid in an experimental model of Parkinson’s disease[J].Metab Brain Dis，2021，36（5）：1003-1014
    [61] DA SILVA F L，COELHO CERQUEIRA E，DE FREITAS M S，et al.Vitamins K interact with N ⁃terminus α⁃synu-clein and modulate the protein fibrillization in vitro.Exploring the interaction between quinones and α⁃ synu-clein[J].Neurochem Int，2013，62（1）：103-112
    [62] JING X，WEI X B，REN M R，et al.Neuroprotective effects of tanshinoneⅠagainst 6⁃OHDA ⁃induced oxidative stress in cellular and mouse model of Parkinson’s disease through upregulating Nrf2[J].Neurochem Res，2016，41（4）：779-786
    [63] SUBEDI L，GAIRE B P.TanshinoneⅡA：a phytochemical as a promising drug candidate for neurodegenerative diseases[J].Pharmacol Res，2021，169：105661
    [64] PERNI M，GALVAGNION C，MALTSEV A，et al.A natural product inhibits the initiation of α⁃synuclein aggregation and suppresses its toxicity[J].Proc Natl Acad Sci U S A，2017，114（6）：E1009-E1017
    [65] ZHANG R Y，SUN F L，ZHANG L，et al.Tetrahydroxys-tilbene glucoside inhibits α ⁃ synuclein aggregation and apoptosis in A53T α⁃synuclein⁃transfected cells exposed to MPP[J].Can J Physiol Pharmacol，2017，95（6）：750-758
    [66] FENG S L，GUI J J，QIN B Q，et al.Resveratrol inhibits VDAC1 ⁃ mediated mitochondrial dysfunction to mitigate pathological progression in Parkinson’s disease model[J/OL].Mol Neurobiol，2024，DOI：10.1007/s12035 ⁃ 024 ⁃ 04234⁃0
    [67] ALBANI D，POLITO L，BATELLI S，et al.The SIRT1 activator resveratrol protects SK ⁃N ⁃BE cells from oxidative stress and against toxicity caused by alpha-synuclein or amyloid⁃beta（1⁃42）peptide[J].J Neurochem，2009，110（5）：1445-1456
    [68] SASHIDHARA K V，MODUKURI R K，JADIYA P，et al.Discovery of 3⁃arylcoumarin⁃tetracyclic tacrine hybrids as multifunctional agents against Parkinson’s disease[J].ACS Med Chem Lett，2014，5（10）：1099-1103
    [69] WANG Z P，ZHANG W，XING L Z，et al.Therapeutic potential of coumarin-polyphenolic acid hybrids in PD：inhibition of α ⁃ syn aggregation and disaggregation of preformed fibrils，leading to reduced neuronal inclusion formation[J].Bioorg Med Chem Lett，2024，99：129618
    [70] RAMIREZ E，GANEGAMAGE S K，ELBATRAWY A A，et al.5⁃Nitro⁃1，2⁃benzothiazol⁃3⁃amine and N⁃ethyl⁃1⁃ [（ethylcarbamoyl）（5⁃nitro⁃1，2⁃benzothiazol⁃3⁃yl）amino] formamide modulate α⁃synuclein and Tau aggregation[J].ACS Omega，2023，8（22）：20102-20115
    [71] ZHAO Y D，ZHANG W，XING L Z，et al.In vitro inhibition of α⁃synuclein aggregation and disaggregation of preformed fibers by polyphenol hybrids with 2 ⁃ conjugated benzothiazole[J].Bioorg Med Chem Lett，2024，105：129752
    [72] ZHANG W，LIU W，ZHAO Y D，et al.The potential of Rhein’s aromatic amines for Parkinson’s disease prevention and treatment：α ⁃ synuclein aggregation inhibition and disaggregation of preformed fibers[J].Bioorg Med Chem Lett，2024，97：129564
    [73] SINGH P，AKHTAR A，ADMANE N，et al.The antiviral drug ribavirin effectively modulates the amyloid transformation of α ⁃ synuclein protein[J].Comput Biol Chem，2024，112：108155
    [74] CUI Z，GUO F Y，LI L，et al.Brazilin⁃7⁃acetate，a novel potential drug of Parkinson’s disease，hinders the formation of α ⁃ synuclein fibril，mitigates cytotoxicity，and decreases oxidative stress[J].Eur J Med Chem，2024，264：115965
    [75] XING L Z，ZHANG W，ZHAO Y D，et al.Pyrazolamide derivatives inhibit α⁃ synuclein aggregation，disaggregate preformed fibers，and reduce inclusion formation in neuron cells[J].Eur J Med Chem，2024，268：116198
    引证文献
    网友评论
    网友评论
    分享到微博
    发 布
引用本文

李奇,秦亚娟,唐立钧.帕金森病标志物α⁃突触核蛋白聚集抑制剂的研究进展[J].南京医科大学学报（自然科学版）,2025,(3):404-417

复制
分享
文章指标
  • 点击次数:635
  • 下载次数: 29
  • HTML阅读次数: 11
  • 引用次数: 0
历史
  • 收稿日期:2024-11-18
  • 在线发布日期: 2025-03-17

友情链接 Links

技术支持：北京勤云科技发展有限公司
关闭